In the possible event of a pandemic, the UK has secured 5 million doses of an H5 influenza vaccine to stay one step ahead of the avian influenza virus
CSL Seqirus UK Limited manufactures the vaccine, which is extracted from a current H5 avian influenza virus. The plan is to improve access to vaccines targeting pathogens with pandemic potential.
What is Avian influenza, and how is it a global threat?
Avian influenza A(H5N1) has been at the centre of a prolonged global outbreak, mainly affecting bird populations.
While there is no evidence to suggest human-to-human transmission at this stage, the vaccine has been acquired as a precautionary measure. It will only be used if the virus begins to spread among humans.
This new measure ensures the availability of a pre-made vaccine.
Pandemic preparedness
Vaccines are a cornerstone of public health defence, and securing supplies in advance of potential outbreaks enables faster responses that save lives.
The government already maintains advanced purchase agreements for pandemic-specific vaccines, which are so rapid to respond to outbreaks.
The addition of the H5 vaccine is an extension of the UK’s established pandemic preparedness plans.
Specific pandemic-tailored vaccines are being developed in the UK to address any new flu strains that emerge.
In addition to vaccine procurement, the UK’s preparedness framework includes extensive surveillance programs, research efforts, and response strategies.
Monitoring avian influenza
Key organisations, such as the UK Health Security Agency (UKHSA) and the Animal and Plant Health Agency (APHA), play an important role in monitoring and responding to avian influenza risks.
The UKHSA actively tracks potential human cases, while the APHA conducts targeted surveillance and testing in wild and farmed bird populations.
Both agencies use genomic sequencing and other advanced techniques to support early detection and response efforts, leading to a better understanding of the disease.
Learning from COVID-19
The partnership with CSL Seqirus shows the role of collaboration between government and industry in pandemic preparedness.
As a global leader in outbreak response, CSL Seqirus is key to the UK’s efforts to ensure rapid response capabilities against evolving health threats.
By adding the H5 influenza vaccine to its stockpile, the UK government is reinforcing its resilience against emerging health threats. This strategic step shows the commitment to pandemic preparedness four years after COVID-19, ensuring that the nation is alert and capable of responding effectively to global health concerns.
Having learnt from the COVID pandemic, the UK government hopes this vaccine will prevent a situation like that again. Keeping people safe and the economy stronger.
